ECSP034455A - Forma de dosificacion de farmaco activada por hidrogel - Google Patents

Forma de dosificacion de farmaco activada por hidrogel

Info

Publication number
ECSP034455A
ECSP034455A EC2003004455A ECSP034455A ECSP034455A EC SP034455 A ECSP034455 A EC SP034455A EC 2003004455 A EC2003004455 A EC 2003004455A EC SP034455 A ECSP034455 A EC SP034455A EC SP034455 A ECSP034455 A EC SP034455A
Authority
EC
Ecuador
Prior art keywords
core
dosage form
pharmaco
hydrogel
activated
Prior art date
Application number
EC2003004455A
Other languages
English (en)
Inventor
William Jhon Curatolo
Scott Max Herbig
Dwayne Thomas Friesen
Walter C Babcock
Avinash Govind Thombre
Leah Elizabeth Appel
Mark Brian Chidlaw
Ronald Arthur Beyerinck
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034455A publication Critical patent/ECSP034455A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación de liberación controlada comprende un núcleo recubierto, comprendiendo el núcleo una composición que contiene fármaco y una composición hinchable con agua y ocupando cada una regiones separadas dentro del núcleo. El recubrimiento que rodea el núcleo es permeable al agua, insoluble en agua y tiene al menos una abertura de suministro. Se describen una diversidad de configuraciones geométricas.
EC2003004455A 2000-08-09 2003-01-28 Forma de dosificacion de farmaco activada por hidrogel ECSP034455A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
ECSP034455A true ECSP034455A (es) 2003-03-10

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004455A ECSP034455A (es) 2000-08-09 2003-01-28 Forma de dosificacion de farmaco activada por hidrogel

Country Status (30)

Country Link
US (2) US20030086972A1 (es)
EP (1) EP1326587A2 (es)
JP (1) JP2004505907A (es)
KR (1) KR20030024844A (es)
CN (1) CN1461212A (es)
AP (1) AP2001002237A0 (es)
AU (1) AU2002229141A1 (es)
BG (1) BG107538A (es)
BR (1) BR0113067A (es)
CA (1) CA2418907A1 (es)
DO (1) DOP2001000229A (es)
EA (1) EA200300081A1 (es)
EC (1) ECSP034455A (es)
EE (1) EE200300055A (es)
GT (1) GT200100161A (es)
HR (1) HRP20030082A2 (es)
HU (1) HUP0300722A2 (es)
IL (1) IL154012A0 (es)
IS (1) IS6686A (es)
MA (1) MA26939A1 (es)
MX (1) MXPA03001209A (es)
NO (1) NO20030627L (es)
OA (1) OA12365A (es)
PA (1) PA8524901A1 (es)
PE (1) PE20020307A1 (es)
PL (1) PL360658A1 (es)
SV (1) SV2002000586A (es)
TN (1) TNSN01123A1 (es)
UY (1) UY26876A1 (es)
WO (1) WO2002011702A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
GEP20043334B (en) * 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
BRPI0206432A2 (pt) 2001-01-12 2016-10-25 Sun Pharmaceutical Ind Ltd métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
CA2461653A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Edible composition and dosage form comprising an edible shell
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR101363679B1 (ko) * 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
WO2004028512A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage form with two cores
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
BRPI0413363A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
WO2006082500A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
EP1858493A4 (en) * 2005-03-14 2010-12-01 Sun Pharmaceutical Ind Ltd SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
EP2012706A4 (en) * 2006-04-20 2013-02-13 Transport Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC METHOTREXATE RELEASE
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
MX2010008861A (es) * 2008-02-15 2011-02-22 Sun Pharma Advanced Res Co Ltd Tableta oral de liberacion controlada con efecto de liberacion masiva reducido.
BR112012010895A2 (pt) * 2009-11-09 2019-09-24 Capsugel Belgium Nv "fornecimento de veículo".
CN102791271B (zh) 2010-03-19 2014-05-14 第一三共株式会社 抗凝剂的溶出改善方法
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
ES2725879T3 (es) * 2013-01-30 2019-09-30 Daewoong Co Ltd Composición farmacéutica para la protección de heridas, para proporcionar una hemostasia o para evitar la adhesión en el tracto gastrointestinal
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
US10350822B1 (en) * 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
CA3088017A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
IL307342A (en) * 2021-05-28 2023-11-01 Amgen Inc Formulations of apremilast
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
TW202325285A (zh) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 粉末製劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
PL179910B1 (pl) * 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EA002481B1 (ru) * 1997-07-01 2002-06-27 Пфайзер Продактс Инк. Композиция на основе солюбилизированного сертралина
NZ513456A (en) * 1997-07-01 2003-02-28 Pfizer Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
PL348119A1 (en) * 1998-10-13 2002-05-06 Pfizer Prod Inc Sertraline oral concentrate
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PL377479A1 (pl) * 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Also Published As

Publication number Publication date
MXPA03001209A (es) 2003-06-30
US20040052845A1 (en) 2004-03-18
JP2004505907A (ja) 2004-02-26
CA2418907A1 (en) 2002-02-14
WO2002011702A3 (en) 2002-11-28
EE200300055A (et) 2004-12-15
DOP2001000229A (es) 2002-09-30
HRP20030082A2 (en) 2003-04-30
IS6686A (is) 2003-01-16
EP1326587A2 (en) 2003-07-16
NO20030627L (no) 2003-04-08
MA26939A1 (fr) 2004-12-20
WO2002011702A2 (en) 2002-02-14
BR0113067A (pt) 2003-07-01
CN1461212A (zh) 2003-12-10
BG107538A (bg) 2003-11-28
UY26876A1 (es) 2002-03-22
IL154012A0 (en) 2003-07-31
HUP0300722A2 (hu) 2003-11-28
PA8524901A1 (es) 2002-04-25
GT200100161A (es) 2002-03-22
TNSN01123A1 (fr) 2005-11-10
KR20030024844A (ko) 2003-03-26
SV2002000586A (es) 2002-10-24
OA12365A (en) 2006-05-16
EA200300081A1 (ru) 2003-08-28
AP2001002237A0 (en) 2001-09-30
US20030086972A1 (en) 2003-05-08
PL360658A1 (en) 2004-09-20
PE20020307A1 (es) 2002-04-23
NO20030627D0 (no) 2003-02-07
AU2002229141A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
ECSP034455A (es) Forma de dosificacion de farmaco activada por hidrogel
GT200000222A (es) Forma de dosificacion de farmacos accionada por un hidrogel.
PA8508901A1 (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
DE60018777D1 (de) Medikamentenversorgung der sub-tenon
ATE227597T1 (de) Implantat
UY25544A1 (es) Forma de dosificación de nefazodona
DE60108255D1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
CL2007003010A1 (es) Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
BR0314787A (pt) Forma de dosagem de liberação modificada
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
UY28461A1 (es) Composición nueva
ECSP003856A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
ES2187440T3 (es) Utilizacion de orosomucoide en un preparado farmaceutico para el tratamiento de pancreatitis aguda.
ECSP003853A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
CO5190687A1 (es) Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes
AR033431A1 (es) Composiciones farmaceuticas de sabor enmascarado.